Jun 23, 2022 by Natalie ForbesWhy Investors Should Focus on Abbott's Medical DevicesAdvances in the core business highlight stable growth prospects.
Jun 20, 2022 by Natalie ForbesWhy Eli Lilly's Immunology Prospects Look PromisingUplifting news turns the tide in immunology.
Jun 3, 2022 by Natalie ForbesWhy Pfizer Needs a High-Growth PipelineThe company moves to build a solid lineup to replace COVID-19 revenue that just can't last.
Jun 1, 2022 by Natalie ForbesWhy Rising Farming Costs May Actually Help John DeereThe tractor giant's new tech could let farmers work more efficiently.
May 26, 2022 by Natalie ForbesWhy Regeneron Investors Shouldn't Fear Its Patent CliffNew treatments will step in to replace blockbuster eye medication EYLEA.
May 24, 2022 by Natalie ForbesWhy Roche Needs to Invest in At-Home DiagnosticsDeclining demand for COVID-19 screening tests calls for a new focus.
May 17, 2022 by Natalie ForbesHow the Infant Formula Recall Will Impact Abbott's RevenueBig losses in the company's offerings for tiny people might not be as bad as they seem.
May 12, 2022 by Natalie ForbesHow Novo Nordisk Will Protect Insulin SalesAdvancing insulin technology promises a better patient experience.
May 7, 2022 by Natalie ForbesWhy GSK May Have Bet Too Big on a Pandemic PipelineIts late-stage pipeline is heavily weighted toward pandemic treatments.
May 3, 2022 by Natalie ForbesWhy CSX Could Remain Dominant in Freight TransportIts investment in rail-to-highway transport increases exposure to trends in freight trucking.
Apr 28, 2022 by Natalie ForbesWhy Surgical Innovation Should Boost Medtronic's GrowthIts entry into the booming robotic surgery space may unlock additional revenue.
Apr 23, 2022 by Natalie ForbesDoes Eli Lilly's Future Depend on its Alzheimer's Drug?Medicare's decision raises uncertainty about a key upcoming treatment.
